Shield Therapeutics PLC PDMR Transaction Notification (8171U)
27 Novembre 2023 - 6:24PM
UK Regulatory
TIDMSTX
RNS Number : 8171U
Shield Therapeutics PLC
27 November 2023
Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
PDMR Transaction Notification
London, UK, 27 November 2023: Shield Therapeutics plc (LSE:STX),
a commercial stage pharmaceutical company with a focus on
addressing iron deficiency with its lead product
Accrufer(R)/Feraccru(R) (ferric maltol), confirms that Mr Hans
Peter Hasler, Chairman, acquired 2,000,000 Ordinary Shares in the
Company on 21 November 2023 at a price of 6.1p per share. Mr Hasler
now holds a beneficial interest in 5,500,000 Ordinary Shares.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them:
1. Details of the person discharging managerial responsibilities / person closely associated
a. Name Hans Peter Hasler
-------------------------------- -------------------------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------------------
a. Position/status Chairman
-------------------------------- -------------------------------------------------------------
b. Initial notification Initial
/Amendment
-------------------------------- -------------------------------------------------------------
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-----------------------------------------------------------------------------------------------
a. Name Shield Therapeutics plc
-------------------------------- -------------------------------------------------------------
b. LEI 213800G74QWY15FC3W71
-------------------------------- -------------------------------------------------------------
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------------------------------
a. Description of the Ordinary shares of 1.5p each in the capital of the Company
Financial instrument, type
of instrument
Identification code
ISIN of Ordinary Shares: GB00BYV81293
-------------------------------- -------------------------------------------------------------
b. Nature of the transaction Acquisition of Ordinary Shares
-------------------------------- -------------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
6.1p 2,000,000
----------
-------------------------------- -------------------------------------------------------------
d. Aggregated information
* Aggregated volume 2,000,000
GBP122,000
* Price
-------------------------------- -------------------------------------------------------------
e. Date of the transaction 21 November 2023
-------------------------------- -------------------------------------------------------------
f. Place of the transaction AIM
-------------------------------- -------------------------------------------------------------
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Patrick Birkholm +44 (0)20 7418 8900
Joint Broker
Cavendish Capital Markets Ltd
Geoff Nash/ George Dollemore/Nigel
Birks +44 (0)20 7220 0563
Financial PR & IR Advisor
Walbrook PR
Paul McManus/ Alice Woodings +44 (0)20 7933 8780 or shield@walbrookpr.com
Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com
About Iron Deficiency and Accrufer(R)/Feraccru(R)
Clinically low iron levels (aka iron deficiency, ID) can cause
serious health problems for adults of all ages, across multiple
therapeutic areas. Together, ID and ID with anemia (IDA) affect
about 20 million people in the US and represent a $2.3B market
opportunity. As the first and only FDA approved oral iron to treat
ID/IDA, Accrufer(R) has the potential to meet an important unmet
medical need for both physicians and patients.
Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable,
non-salt-based oral therapy for adults with ID/IDA.
Accrufer(R)/Feraccru(R) has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an
efficacious and well-tolerated therapy in a range of clinical
trials. More information about Accrufer(R)/ Feraccru(R) , including
the product label, can be found at: www.accrufer.com and
www.feraccru.com .
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company
that delivers Accrufer(R)/Feraccru(R) (ferric maltol), an
innovative and differentiated pharmaceutical product, to address a
significant unmet need for patients suffering from iron deficiency,
with or without anemia. The Company launched Accrufer(R) in the
U.S. with an exclusive, multi-year collaboration agreement with
Viatris. Outside of the U.S., the Company licensed the rights to
four specialty pharmaceutical companies. Feraccru(R) is
commercialized in the UK and European Union by Norgine B.V.
(Norgine), which also has marketing rights in Australia and New
Zealand. Shield also has an exclusive license agreement with
Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialization of Accrufer(R)/ Feraccru(R) in China, Hong Kong,
Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of
Korea (Korea Pharma), and with KYE Pharmaceuticals Inc. for
Canada.
Accrufer(R)/Feraccru(R) has patent coverage until the
mid-2030s.
Accrufer(R)/Feraccru(R) are registered trademarks of Shield
Therapeutics.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPGPPGUPWGMM
(END) Dow Jones Newswires
November 27, 2023 12:24 ET (17:24 GMT)
Shield Therapeutics (LSE:STX)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Shield Therapeutics (LSE:STX)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
